trending Market Intelligence /marketintelligence/en/news-insights/trending/ShUDPstqLrC31P97uUc8AQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biohaven raises $143.7M in public offering of common shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biohaven raises $143.7M in public offering of common shares

Biohaven Pharmaceutical Holding Co. Ltd. raised $143.7 million in a public offering of common shares after the underwriters fully exercised their options.

The company issued 3,859,060 common shares at $37.25 each for the offering, including the full exercise of underwriters' option to purchase additional shares. Expected gross proceeds had been set at $125 million.

Goldman Sachs & Co. LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering, with Morgan Stanley and Cantor Fitzgerald & Co. as book runners. William Blair is the co-manager of the offering.

New Haven, Conn.-based Biohaven Pharmaceutical Holding is a clinical‑stage biopharmaceutical company that develops product candidates targeting migraine and neurological diseases, including rare disorders.